Pegloticase

Polyethylene glycol (PEG) is crucial in medical applications, enhancing drug bioavailability and reducing immunogenicity. However, PEGylated nanopharmaceuticals have caused side effects, particularly after intravenous administration. PEG's mechanism of side effects is unclear but may involve immune response stimulation. Studies show PEG can induce cytokine production and neutrophil extracellular trap formation, potentially through Ca²⁺ signaling, highlighting the need for further research on PEG's immunological effects.

Amgen presents new data on UPLIZNA for IgG4-RD and KRYSTEXXA for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times.

Protalix Biotherapeutics announced 3Q24 financial results, with $18M revenue (+74% YoY), driven by Chiesi revenues. Net income was $3.2M, or $0.03 per share. PRX-115 Phase I trial in gout completed, showing dose-dependent urate reduction and safety. Phase II planned for 2H25.

Amgen presents new data on UPLIZNA® for IgG4-RD and KRYSTEXXA® for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times, respectively.

Amgen presents new data on UPLIZNA® for IgG4-RD and KRYSTEXXA® for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times, respectively.

Amgen's Q3 2024 revenue surged 23% to $8.5bn, driven by 24% product sales growth, including ten double-digit growth products. The innovative oncology portfolio grew 17%, and the rare disease portfolio saw a 21% YOY increase to $1.2bn, boosted by Horizon Therapeutics' acquisitions. Amgen discontinued the LPAR1 antagonist study due to Phase II failure but plans to share Phase II MariTide data in late 2024 and initiate a Phase III program for obesity and T2D.

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.

Fennec Pharmaceuticals appoints Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer to strengthen its executive team and accelerate the commercialization of PEDMARK, the first therapy to reduce ototoxicity risk from cisplatin treatment in pediatric patients.

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.